JP2022500461A5 - - Google Patents

Info

Publication number
JP2022500461A5
JP2022500461A5 JP2021514550A JP2021514550A JP2022500461A5 JP 2022500461 A5 JP2022500461 A5 JP 2022500461A5 JP 2021514550 A JP2021514550 A JP 2021514550A JP 2021514550 A JP2021514550 A JP 2021514550A JP 2022500461 A5 JP2022500461 A5 JP 2022500461A5
Authority
JP
Japan
Prior art keywords
corneal region
patient
composition according
dryness
region
Prior art date
Application number
JP2021514550A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2020058504A5 (https=
JP2022500461A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2019/075406 external-priority patent/WO2020058504A1/en
Publication of JP2022500461A publication Critical patent/JP2022500461A/ja
Publication of JPWO2020058504A5 publication Critical patent/JPWO2020058504A5/ja
Publication of JP2022500461A5 publication Critical patent/JP2022500461A5/ja
Pending legal-status Critical Current

Links

JP2021514550A 2018-09-22 2019-09-20 眼表面の損傷および乾燥の症状の治療のための眼科用組成物 Pending JP2022500461A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
EP18196126 2018-09-22
EP18196126.9 2018-09-22
EP18198440 2018-10-03
EP18198440.2 2018-10-03
EP18202041.2 2018-10-23
EP18202041 2018-10-23
PCT/EP2019/075406 WO2020058504A1 (en) 2018-09-22 2019-09-20 Ophthalmic compositions for treatment of ocular surface damage and symptoms of dryness

Publications (3)

Publication Number Publication Date
JP2022500461A JP2022500461A (ja) 2022-01-04
JPWO2020058504A5 JPWO2020058504A5 (https=) 2022-09-27
JP2022500461A5 true JP2022500461A5 (https=) 2022-09-27

Family

ID=68240699

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021514550A Pending JP2022500461A (ja) 2018-09-22 2019-09-20 眼表面の損傷および乾燥の症状の治療のための眼科用組成物

Country Status (11)

Country Link
US (2) US20210346313A1 (https=)
EP (1) EP3852734A1 (https=)
JP (1) JP2022500461A (https=)
KR (1) KR20210080388A (https=)
CN (1) CN112739335A (https=)
AU (2) AU2019342426A1 (https=)
CA (1) CA3111873A1 (https=)
IL (1) IL281516A (https=)
PH (1) PH12021550621A1 (https=)
SG (1) SG11202102818YA (https=)
WO (1) WO2020058504A1 (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108348777B (zh) 2015-09-30 2020-04-28 诺瓦利克有限责任公司 半氟化化合物和其组合物
USRE50060E1 (en) 2016-06-23 2024-07-30 Novaliq Gmbh Topical administration method
ES2969758T3 (es) 2016-09-22 2024-05-22 Novaliq Gmbh Composiciones farmacéuticas para usar en la terapia de la blefaritis
US10813976B2 (en) 2016-09-23 2020-10-27 Novaliq Gmbh Ophthalmic compositions comprising ciclosporin
PT3399962T (pt) 2016-12-23 2020-09-03 Novaliq Gmbh Composição oftálmica para o tratamento da doença do olho seco
CA3058097C (en) 2017-04-21 2024-01-02 Novaliq Gmbh Iodine compositions
KR20200059272A (ko) 2017-09-27 2020-05-28 노바리크 게엠베하 안구 질환의 치료에서의 사용을 위한 라타노프로스트를 포함하는 안과적 조성물
CN111182893A (zh) 2017-10-04 2020-05-19 诺瓦利克有限责任公司 包含f6h8的眼用组合物
EP3758676A1 (en) 2018-03-02 2021-01-06 Novaliq GmbH Pharmaceutical compositions comprising nebivolol
KR102882058B1 (ko) 2018-03-28 2025-11-07 노바리크 게엠베하 티몰롤을 포함하는 약제학적 조성물
JP2021522219A (ja) 2018-04-27 2021-08-30 ノバリック ゲーエムベーハー 緑内障の治療のためのタフルプロストを含む眼科用組成物
CN113710228A (zh) 2019-02-13 2021-11-26 诺瓦利克有限责任公司 用于治疗眼部新生血管形成的组合物和方法
US12419933B2 (en) 2019-09-06 2025-09-23 Novaliq Gmbh Ophthalmic composition for the treatment of uveitis

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19938668B4 (de) 1999-08-14 2006-01-26 Bausch & Lomb Inc. Tränenersatzmittel
EP1494681A4 (en) * 2002-04-16 2008-08-06 Collagenex Pharm Inc PROCESS FOR THE SIMULTANEOUS TREATMENT OF OCULAR ROSACEA AND ACNE ROSACEA
US10105441B2 (en) * 2007-08-16 2018-10-23 The Schepens Eye Research Institute, Inc. Method for inhibiting or reducing dry eye disease by IL-1Ra
EP2335735A1 (en) 2009-12-14 2011-06-22 Novaliq GmbH Pharmaceutical composition for treatment of dry eye syndrome
CN113679697A (zh) 2012-09-12 2021-11-23 诺瓦利克有限责任公司 包含半氟化烷烃的混合物的组合物
DK3181119T3 (da) * 2012-09-12 2019-09-16 Novaliq Gmbh Semifluorerede alkansammensætninger til anvendelse ved behandling af keratoconjunctivitis sicca
CN106999402B (zh) * 2014-10-09 2020-10-27 梅迪普罗都司股份有限公司 睫毛用清洗剂
CN108348777B (zh) * 2015-09-30 2020-04-28 诺瓦利克有限责任公司 半氟化化合物和其组合物
ES2969758T3 (es) * 2016-09-22 2024-05-22 Novaliq Gmbh Composiciones farmacéuticas para usar en la terapia de la blefaritis
CN111182893A (zh) * 2017-10-04 2020-05-19 诺瓦利克有限责任公司 包含f6h8的眼用组合物

Similar Documents

Publication Publication Date Title
JP2022500461A5 (https=)
Murray et al. The eye and inflammatory rheumatic diseases: The eye and rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis
Baudouin et al. Inflammation in Glaucoma: From the back to the front of the eye, and beyond
Nijm et al. Understanding the dual dilemma of dry eye and glaucoma: an international review
JP2024116245A5 (https=)
Jaenen et al. Ocular symptoms and signs with preserved and preservative-free glaucoma medications
Park et al. Clinical effects and safety of 3% diquafosol ophthalmic solution for patients with dry eye after cataract surgery: a randomized controlled trial
Federici The non-antibiotic properties of tetracyclines: clinical potential in ophthalmic disease
US11865123B2 (en) Methods of inhibiting pathological angiogenesis
JP2015509500A5 (https=)
JPWO2020074697A5 (https=)
WO2019033119A1 (en) TREATMENT OF OPHTHALMIC CONDITIONS SUCH AS MACULAR DEGENERATION, GLAUCOMA AND DIABETIC RETINOPATHY USING PHARMACEUTICAL AGENTS THAT ELIMINATE SENESCENT CELLS
KR20210080388A (ko) 안구 표면 손상 및 건조 증상 치료를 위한 안약 조성물
Lazreg et al. Efficacy and safety of preservative-free timolol 0.1% gel in open-angle glaucoma and ocular hypertension in treatment-naïve patients and patients intolerant to other hypotensive medications
JPWO2020058504A5 (https=)
AU2020290443A1 (en) Carabachol-bromonidine formulation to enhance anti-presbyopia effects
Voss et al. Non-infectious and non-hereditary diseases of the corneal epithelium
US20230338307A1 (en) Prophylactic agent, ameliorating agent, and therapeutic agent for dry eye
Hashemian et al. Ocular presentations of amyloidosis
Bruce et al. Anterior eye disease and therapeutics AZ
El Fekih et al. Successful management of dry eye disease with a new eye drop formulation combining hyaluronic acid, trehalose, and N-acetyl-aspartyl-glutamic acid (NAAGA)
US20240216375A1 (en) Use of sympathetic activation inhibitor and/or alpha 1-adrenergic receptor inhibitor in preparing medicine for treating dry eyes
CN114040783A (zh) 可用于治疗干眼症的组合物和方法
RU2021107208A (ru) Офтальмологические композиции для лечения повреждения поверхности глаза и симптомов сухости глаз
Qian et al. Efficacy of 0.05% cyclosporine A on tear inflammatory cytokines and goblet cell function after corneal refractive surgery